Curcumin in Combination With 5FU for Colon Cancer

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to test the safety and find the response rate of combining the dietary supplement, curcumin, with the standard of care, FDA-approved chemotherapy drug 5-fluorouracil (5FU, Adracil) and see what effects (good and bad) that the combined treatments have on colon cancer.

Clinical Trial Description

Confirm clinical safety and identify clinical response rate of combination treatment with curcumin and 5FU in chemorefractory CRC patients. To determine whether curcumin administration induces systemic alterations in inflammatory and epigenetic biomarkers in patients with chemoresistant metastatic colorectal cancer (CRC). To correlate altered biomarker findings with clinical response according to RECIST V1.1 and survival criteria. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02724202
Study type	Interventional
Source	Baylor Research Institute
Contact
Status	Active, not recruiting
Phase	Early Phase 1
Start date	March 2016
Completion date	June 13, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04186117` - Development of Clinical and Biological Database in Colorectal Cancer	N/A
Completed	`NCT05468892` - Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial	Phase 2
Recruiting	`NCT02291744` - A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients	Phase 2
Active, not recruiting	`NCT00986661` - A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Phase 1
Completed	`NCT03176485` - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors	N/A
Recruiting	`NCT05983367` - A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT03730558` - ZETA : Prospective Observational Study
Recruiting	`NCT06180460` - CALM: Managing Distress in Malignant Brain Cancer	N/A
Active, not recruiting	`NCT03251378` - A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer	Phase 1
Recruiting	`NCT04737213` - SGM-101 in Colorectal Lung Metastases	Phase 2
Recruiting	`NCT05714124` - Liver Embolization Approaches for Tumor Management
Recruiting	`NCT05396807` - REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients	N/A
Withdrawn	`NCT03764137` - Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05848739` - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors	Phase 1
Not yet recruiting	`NCT06202183` - Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial	N/A
Withdrawn	`NCT01936961` - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors	N/A
Not yet recruiting	`NCT06358677` - Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer	Phase 2
Completed	`NCT03415126` - A Study of ASN007 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02834052` - Pembrolizumab + Poly-ICLC in MRP Colon Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06446557` - De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer	Phase 3